Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort

2018 ◽  
Vol 44 (6) ◽  
pp. 465-472 ◽  
Author(s):  
J. Doucet ◽  
C. Verny ◽  
B. Balkau ◽  
A.J. Scheen ◽  
B. Bauduceau
2017 ◽  
Vol 28 (9) ◽  
pp. 2573-2581 ◽  
Author(s):  
D. Martinez-Laguna ◽  
X. Nogues ◽  
B. Abrahamsen ◽  
C. Reyes ◽  
C. Carbonell-Abella ◽  
...  

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Jin Jin Kim ◽  
Young Choi ◽  
Kwan Yong Lee ◽  
Young Soo Lee ◽  
Ha-Wook Park ◽  
...  

Introduction: We investigated the association between carotid plaque and the presence, extent and severity coronary atherosclerosis using coronary computed tomography angiography (CCTA) and long-term clinical outcome in asymptomatic type 2 diabetic patients. Methods: We consecutively enrolled 788 asymptomatic type 2 diabetic patients without known coronary artery disease (CAD) who underwent CCTA and carotid ultrasound. The presence of carotid plaque was defined as a focal increase in thickness of 1.5 mm or 50% of the surrounding IMT value. We compared the prevalence, extent and severity of coronary atherosclerosis, including coronary artery calcium score (CACS), atheroma burden obstructive score (ABOS), segment involvement score (SIS), and segment stenosis score (SSS) between groups. All-cause mortality during 5 years follow-up was also compared. Results: Higher rates of obstructive CAD (p<0.001) and multi-vessel disease (p<0.005) were noted for patients with carotid plaque. Patients with carotid plaque showed greater degree of CACS, ABOS, SIS, and SSS (p<0.001 for all) on CCTA scans, and had a higher risk of all-cause mortality (p=0.025). The presence of carotid plaque was associated with an increased risk of significant coronary stenosis, independent of conventional cardiovascular risk factors (odds ratio 2.102, confidence interval 1.454-3.039, p<0.001). Conclusions: The presence of carotid plaque is associated with the increased prevalence, extent and severity of coronary atherosclerosis on CCTA and the risk of all-cause mortality. Moreover, carotid plaque was an independent predictor for significant coronary stenosis in asymptomatic type 2 diabetic patients.


Cytokine ◽  
2019 ◽  
Vol 117 ◽  
pp. 59-64 ◽  
Author(s):  
Ran Tian ◽  
Mao Tian ◽  
Liang Wang ◽  
Hao Qian ◽  
Shuyang Zhang ◽  
...  

2007 ◽  
Vol 19 (6) ◽  
pp. 492-496 ◽  
Author(s):  
Matteo Monami ◽  
Lorella Lambertucci ◽  
Caterina Lamanna ◽  
Elena Lotti ◽  
Alberto Marsili ◽  
...  

2019 ◽  
Vol 104 (10) ◽  
pp. 4900-4908 ◽  
Author(s):  
Massimiliano Copetti ◽  
Hetal Shah ◽  
Andrea Fontana ◽  
Maria Giovanna Scarale ◽  
Claudia Menzaghi ◽  
...  

AbstractContextWe previously developed and validated an inexpensive and parsimonious prediction model of 2-year all-cause mortality in real-life patients with type 2 diabetes.ObjectiveThis model, now named ENFORCE (EstimatioN oF mORtality risk in type 2 diabetiC patiEnts), was investigated in terms of (i) prediction performance at 6 years, a more clinically useful time-horizon; (ii) further validation in an independent sample; and (iii) performance comparison in a real-life vs a clinical trial setting.DesignObservational prospective randomized clinical trial.SettingWhite patients with type 2 diabetes.PatientsGargano Mortality Study (GMS; n = 1019), Foggia Mortality Study (FMS; n = 1045), and Pisa Mortality Study (PMS; n = 972) as real-life samples and the standard glycemic arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) clinical trial (n = 3150).Main Outcome MeasureThe endpoint was all-cause mortality. Prediction accuracy and calibration were estimated to assess the model's performances.ResultsENFORCE yielded 6-year mortality C-statistics of 0.79, 0.78, and 0.75 in GMS, FMS, and PMS, respectively (P heterogeneity = 0.71). Pooling the three cohorts showed a 6-year mortality C-statistic of 0.80. In the ACCORD trial, ENFORCE achieved a C-statistic of 0.68, a value significantly lower than that obtained in the pooled real-life samples (P < 0.0001). This difference resembles that observed with other models comparing real-life vs clinical trial settings, thus suggesting it is a true, replicable phenomenon.ConclusionsThe time horizon of ENFORCE has been extended to 6 years and validated in three independent samples. ENFORCE is a free and user-friendly risk calculator of all-cause mortality in white patients with type 2 diabetes from a real-life setting.


Sign in / Sign up

Export Citation Format

Share Document